Objective The androgen receptor-targeting drugs abiraterone acetate and enzalutamide
have shown positive results as treatments for metastatic castration-resistant prostate cancer …

Current treatments for castration resistant prostate cancer (CRPC) largely fall into two
classes: androgen receptor (AR)-targeted therapies such as the next-generation …

Background Enzalutamide and abiraterone acetate plus prednisone, which target the
androgen receptor axis, have expanded the treatment of advanced prostate cancer …

Importance We previously showed that detection of androgen receptor splice variant 7 (AR-
V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer …

While circulating tumor cell (CTC)–based detection of AR-V7 has been demonstrated to
predict patient response to second-generation androgen receptor therapies, the rarity of AR …

Background Abiraterone acetate (abiraterone) prolongs overall survival (OS) in patients with
metastatic castration-resistant prostate cancer (mCRPC). This study's objective was to …

Purpose Evidence suggests differences in androgen receptor AR signaling between black
(B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) …

In 2014, a landmark study was published demonstrating that the expression of androgen
receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to …

Context Various molecular mechanisms play a role in the development of resistance to
androgen deprivation therapy in castration-resistant prostate cancer (CRPC). Objective To …

Androgen receptor (AR) splice variants (SV) have been implicated in the development of
metastatic castration-resistant prostate cancer and resistance to AR targeting therapies …